1. Kaukinen K, Partanen J, Mäki M, Collin P. HLA-DQ typing in the diagnosis of celiac disease. Am J Gastroenterol. 2002;97(3):695-699.
2. Pietzak M, Schofield T. HLA-DQ2 homozygotes are associated with a 31-fold increased risk of EMA positivety in a large sample of sera (n = 4152) from patients at risk for celiac disease [DDW abstract]. Gastroenterology. 2007;132(7):2585.
3. Fasano A, Berti I, Gerarduzzi T, et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch Intern Med. 2003;163(3):286-292.
PROMETHEUS Celiac Plus is a laboratory-developed test that was developed and validated under federal Clinical Laboratory Improvement Amendments (CLIA) laboratory guidelines, and is performed exclusively by Prometheus Laboratories Inc.
It has not been cleared or approved by the US FDA. The test is used for clinical purposes and should not be regarded as investigational or for research. Prometheus Laboratories Inc is certified under CLIA as qualified to perform high-complexity clinical laboratory testing and is accredited by the College of American Pathologists (CAP).
This material is provided for general information purposes only, as an educational service for healthcare physicians and their patients. It is not intended as a substitute for medical advice and/or consultation with a physician.